SYSTEM AND METHOD OF VARIABLE DOSE GLUCAGON DELIVERY

• US 20160015890A1
• Filed: 06/09/2015
• Published: 01/21/2016
• Est. Priority Date: 06/09/2014
• Status: Abandoned Application

• Current Assignee: Artificial Pancreas Technologies, Inc.
• Original Assignee: Artificial Pancreas Technologies, Inc.
• Inventors: Dassau, Eyal, Mitragotri, Samir Suresh, Doyle, Francis J. III, Zisser, Howard Craig
• Application Number:
  US14/734,994
• Publication Number:
  US 20160015890A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61M 2202/0486 Glucose
• CPC Class Codes: A61M 2202/064 Powder
• CPC Class Codes: A61M 2202/07 Proteins
• CPC Class Codes: A61M 5/1409 in series, e.g. first substance passing through container holding second substance, e.g. reconstitution systems needle sets A61M5/162
• CPC Class Codes: A61M 5/14248 of the skin patch type
• CPC Class Codes: A61M 5/16827 controlling delivery of multiple fluids, e.g. sequencing, mixing or via separate flow-paths infusion of multiple fluids without using a controller A61M5/1407

Abstract

Disclosed are systems and methods for variable dose glucagon delivery without the need to manually reconstitute the glucagon. These systems and methods mat be utilized with or without a separate continuous glucose monitor. The variability of the dose may be determined manually by the user, caregiver or responder, or by preprogrammed algorithms utilizing the input from an external sensor such as a continuous glucose monitor.

Claims

1. A system for variable dose glucagon delivery to a patient without the need to manually reconstitute the glucagon comprising:

a reconstitution mechanism comprising;

a reconstitution chamber disposed between an inlet and an outlet;

a stabilized solute form of glucagon;

a solute delivery mechanism for metered dosing of said solute glucagon into said reconstitution chamber;

a diluent supply in fluid communication with said reconstitution chamber;

an activation switch that triggers said solute delivery mechanism to provide a metered dose of said solute glucagon into said reconstitution chamber, and triggers said diluent supply to provide a metered dose of a diluent into said reconstitution chamber; and

,

a delivery mechanism disposed in fluid communication with said outlet to controllably provide a predetermined amount of a soluble glucagon solution to a tissue of said patient.

2. The system of claim 1, wherein said glucagon is in a solid or semi-solid form.

3. The system of claim 1, wherein said reconstitution mechanism further comprises, said solute glucagon that is deposited on, or introduced upstream, of an insoluble sieve disposed within said reconstitution chamber.

4. The system of claim 3, wherein said insoluble sieve has a mesh size or sieving coefficient sufficient to allow said solute glucagon to sufficiently dissolve before exiting said reconstitution chamber.

5. The system of claim 1, wherein said solute delivery mechanism further comprises:

a motorized mechanism that meters and dispenses precise amounts of said solute glucagon from a reservoir to said reconstitution chamber.

6. The system of claim 1, wherein said solute glucagon further comprises;

lyophilized glucagon.

7. The system of claim 1, wherein said solute glucagon further comprises;

lyophilized glucagon mixed with inert binding agents.

8. The system of claim 1, wherein said activation switch relies upon an input from a human to trigger dosing of said glucagon to said patient.

9. The system of claim 1, wherein said activation switch relies upon a measurement of a physiological condition of said patient to trigger dosing of said glucagon to said patient.

10. The system of claim 1, further comprising:

an insulin reservoir containing insulin; and

,

an insulin pump that pumps insulin through an insulin tube for delivery into said patient.

11. The system of claim 10, wherein said activation switch relies upon a measurement of a physiological condition of said patient to trigger dosing of said glucagon and said insulin to said patient.

12. The system of claim 1, further comprising:

a diluent reservoir containing a supply of said diluent; and

,

a diluent pump that pumps said diluent into said reconstitution chamber to supply a glucagon solution through a glucagon tube for delivery into said patient.

13. A method for providing a variable dose of glucagon that is delivered to a patient without the need to manually reconstitute the glucagon comprising:

metering and dispensing a dose of stabilized solute form of glucagon to a reconstitution chamber;

metering and dispensing a diluent dose to said reconstitution chamber to create a soluble glucagon solution of predetermined concentration;

triggering a release of said glucagon solution from said reconstitution chamber based upon a physiological condition of said patient; and

,

controllably delivering said released glucagon solution to provide a predetermined amount of said soluble glucagon solution to a tissue of said patient.

14. The method of claim 13, further comprising the step:

metering and dispensing said dose of stabilized solute form of glucagon to said reconstitution chamber in a solid or semi-solid form.

15. The method of claim 13, further comprising the step:

depositing said solute glucagon upon, or introducing said solute glucagon upstream, of an insoluble sieve disposed within said reconstitution chamber.

16. The method of claim 15, further comprising the step:

entraining said solute glucagon with said insoluble sieve within said reconstitution chamber thereby allowing said solute glucagon to sufficiently dissolve before exiting said reconstitution chamber.

17. The method of claim 13, further comprising the step:

metering and dispensing a precise amount of said solute glucagon from a reservoir to said reconstitution chamber with a motorized mechanism.

18. The method of claim 13, wherein said step of metering and dispensing a dose of stabilized solute form of glucagon, further comprises:

metering and dispensing said dose comprising lyophilized glucagon.

19. The method of claim 13, wherein said step of metering and dispensing a dose of stabilized solute form of glucagon, further comprises:

metering and dispensing said dose comprising lyophilized glucagon mixed with inert binding agents.

20. The method of claim 13, further comprising the step:

manually triggering a release of said glucagon solution from said reconstitution chamber based upon input from a human.

21. The method of claim 13, further comprising the step:

measuring a physiological condition of said patient and utilizing the result of said measurement for said triggering and said delivery of said glucagon to said patient.

22. The method of claim 13, further comprising the step:

metering and dispensing a precise amount of insulin from a an insulin reservoir through an insulin tube for delivery into said patient.

23. The method of claim 22, further comprising the step:

triggering said metering and dispensing of said glucagon and said insulin to said patient based upon a measurement of a physiological condition of said patient.

24. The method of claim 13, further comprising the step:

providing a diluent reservoir containing said diluent; and

,

pumping said diluent into said reconstitution chamber to supply a glucagon solution through a glucagon tube for delivery into said patient.